Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. Its synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DDR. It is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Its lead WEE1 inhibitor product candidate is ATRN-1051. In addition, it has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. It is also evaluating combination opportunities within its pipeline, including research on the combination of ATRN-119 and ATRN-1051. Its pipeline includes the clinical-stage asset ATRN-119, an ATR inhibitor that is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid tumors having mutations in defined DDR-related genes.
More about the company